Biotech M&A speculation involving Incyte, AbbVie, and Viking Therapeutics, with three Nasdaq-listed names under watch.
1 report, 1 independent
Updated Jun 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Biotech M&A speculation involving Incyte, AbbVie, and Viking Therapeutics, with three Nasdaq-listed names under watch.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Incyte acquired Vega Therapeutics to diversify its late-stage pipeline.Sub-event
Incyte and AbbVie are mentioned in biotech M&A context alongside Viking Therapeutics.1 source
Keep exploring
The entities involved
-
Incyte
American pharmaceutical company
-
AbbVie
pharmaceutical company
-
Viking Therapeutics
company in San Diego, United States
- The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.